Chimeric Antigen Recertor Treatment Targeting CD70(Baylor College of Medicine)

N/A

Report date: 2026/03/06 20:02:51

Base Information

Drug NameChimeric Antigen Recertor Treatment Targeting CD70(Baylor College of Medicine)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsCD70 antigen modulators
TargetsCD70 antigen
Therapy Area/IndicationsSolid tumoursKidney NeoplasmsBone Marrow Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsSolid tumoursKidney NeoplasmsBone Marrow Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A